A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

NCT05472259 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Nanoliposomal irinotecan
DRUG: 5 FU
DRUG: Leucovorin
DRUG: Oxaliplatin

Sponsor

Belgian Group of Digestive Oncology

Collaborators

[object Object]